ITCI
Intra-Cellular Therapies Inc

5,810
Mkt Cap
$14.05B
Volume
16.06M
52W High
$131.98
52W Low
$64.09
PE Ratio
-182.70
ITCI Fundamentals
Price
$131.87
Prev Close
$131.92
Open
$131.90
50D MA
$130.09
Beta
0.54
Avg. Volume
2.07M
EPS (Annual)
-$0.7241
P/B
12.20
Rev/Employee
$791,688.37
Loading...
Loading...
News
all
press releases
News Placeholder
Stock Index Futures Climb on Trump Tariffs Report, U.S. PPI Data and Fed Speak in Focus
March S&P 500 E-Mini futures (ESH25) are up +0.49%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.67% this morning as a report indicating the U.S. might take a gradual approach to hiking tariffs boosted sentiment, while investors awaited crucial producer inflation data and comments from Federal Reserve officials.
barchart.com·1y ago
News Placeholder
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million in 2023.
Stocktwits·1y ago
News Placeholder
J&J explores takeover bid for Intra-Cellular Therapies, Bloomberg reports
investing.com·1y ago
<
...
1
>

Latest ITCI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.